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BACKGROUND
Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of 
ischemic events among patients with acute coronary syndromes or previous myo-
cardial infarction. Spontaneous major bleeding and bleeding associated with urgent 
invasive procedures are concerns with ticagrelor, as with other antiplatelet drugs. 
The antiplatelet effects of ticagrelor cannot be reversed with platelet transfusion. 
A rapid-acting reversal agent would be useful.
METHODS
In this randomized, double-blind, placebo-controlled, phase 1 trial, we evaluated in-
travenous PB2452, a monoclonal antibody fragment that binds ticagrelor with high 
affinity, as a ticagrelor reversal agent. We assessed platelet function in healthy volun-
teers before and after 48 hours of ticagrelor pretreatment and again after the ad-
ministration of PB2452 or placebo. Platelet function was assessed with the use of 
light transmission aggregometry, a point-of-care P2Y12 platelet-reactivity test, and 
a vasodilator-stimulated phosphoprotein assay.
RESULTS
Of the 64 volunteers who underwent randomization, 48 were assigned to receive 
PB2452 and 16 to receive placebo. After 48 hours of ticagrelor pretreatment, plate-
let aggregation was suppressed by approximately 80%. PB2452 administered as an 
initial intravenous bolus followed by a prolonged infusion (8, 12, or 16 hours) was 
associated with a significantly greater increase in platelet function than placebo, as 
measured by multiple assays. Ticagrelor reversal occurred within 5 minutes after the 
initiation of PB2452 and was sustained for more than 20 hours (P<0.001 after 
Bonferroni adjustment across all time points for all assays). There was no evidence 
of a rebound in platelet activity after drug cessation. Adverse events related to the 
trial drug were limited mainly to issues involving the infusion site.
CONCLUSIONS
In healthy volunteers, the administration of PB2452, a specific reversal agent for 
ticagrelor, provided immediate and sustained reversal of the antiplatelet effects of 
ticagrelor, as measured by multiple assays. (Funded by PhaseBio Pharmaceuticals; 
ClinicalTrials.gov number, NCT03492385.)
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A ntiplatelet therapy is an essential part of secondary prevention of cardio-vascular events.1,2 In particular, dual anti-
platelet therapy — the combination of aspirin with 
an oral P2Y12 receptor antagonist — is the pre-
dominant approach in patients with acute coro-
nary syndromes, coronary-artery stenting, or pre-
vious myocardial infarction.3-19 The three oral P2Y12 
receptor antagonists that are in use are clopido-
grel, prasugrel, and ticagrelor.
A limitation of all three oral P2Y12 receptor 
antagonists is the increased bleeding risk, which 
persists for several days after drug cessation.20-23 
Establishment of hemostasis can be challenging 
in patients with major bleeding, such as intracra-
nial or gastrointestinal hemorrhage.24,25 In addition, 
urgent invasive procedures, especially emergency 
procedures, are associated with an increased risk 
of periprocedural bleeding. If an emergency pro-
cedure is indicated, the surgeon or proceduralist 
must proceed while accepting the increased bleed-
ing risk, often after empirically providing platelet 
transfusions, despite the ineffectiveness of such 
transfusions in reversing the antiplatelet effects 
of P2Y12 inhibitors. If an urgent procedure is indi-
cated, the proceduralist must either proceed while 
anticipating the increased bleeding risk or post-
pone the procedure for several days while accept-
ing the risks associated with delaying a clinically 
indicated procedure. American College of Cardi-
ology Foundation–American Heart Association, 
European Society of Cardiology, and other society 
guidelines recommend cessation of oral P2Y12 
receptor antagonists at least 3 to 7 days before 
surgery.26,27
Currently, no reversal agents for P2Y12 receptor 
antagonists are known. Unlike the other P2Y12 re-
ceptor antagonists, ticagrelor is a reversible inhibi-
tor, which makes the development of a specific 
reversal agent for ticagrelor feasible. PB2452 
(formerly MEDI2452) is a neutralizing monoclo-
nal antibody fragment that binds ticagrelor and 
its major active circulating metabolite with high 
affinity.28 We hypothesized that PB2452 could be 
used to reverse rapidly the antiplatelet effects of 
ticagrelor, thereby reducing the risk or severity of 
bleeding.
Me thods
Trial Design and Oversight
We conducted a single-center, randomized, double-
blind, placebo-controlled, single-ascending-dose, 
phase 1 trial to evaluate the safety, efficacy, and 
pharmacokinetic profiles of PB2452 in healthy 
volunteers 18 to 50 years of age who were pre-
treated with ticagrelor. As shown in Table S1 in 
the Supplementary Appendix (available with the 
full text of this article at NEJM.org), 10 sequential 
dose cohorts were evaluated. Volunteers in all co-
horts were randomly assigned, in a 3:1 ratio, to 
receive PB2452 or placebo.
Cohorts 1, 2, and 3 each consisted of four vol-
unteers who were randomly assigned to receive a 
30-minute infusion of PB2452 at a dose of 0.1 g, 
0.3 g, and 1.0 g, respectively, or placebo, in the 
absence of ticagrelor pretreatment, to assess the 
initial safety of PB2452. Volunteers in cohorts 4 
through 10 were pretreated with a 180-mg loading 
dose of oral ticagrelor at 7 a.m. on day −2, and 
then with a 90-mg dose every 12 hours starting 
at 7 p.m. on day −2, for a total of five doses and 
48 hours of pretreatment before the evaluation of 
PB2452. Cohorts 4, 5, and 6 each consisted of eight 
volunteers who were assigned to receive a 30-min-
ute infusion of PB2452 at a dose of 1.0 g, 3.0 g, 
and 9.0 g, respectively, or placebo after ticagrelor 
pretreatment. Cohorts 7 through 10 consisted of 
volunteers who were assigned to receive an 18.0-g 
fixed dose of PB2452 according to one of four in-
fusion regimens or placebo after ticagrelor pre-
treatment. In cohorts 7 through 10, PB2452 was 
initiated 2 hours after the administration of the 
last dose of ticagrelor pretreatment to coincide 
with the peak concentration of ticagrelor.29
Volunteers were enrolled at Pharmaceutical 
Product Development, a contract clinical research 
organization. PhaseBio Pharmaceuticals sponsored 
the trial. A steering committee, which consisted of 
academic physicians and a representative from 
PhaseBio Pharmaceuticals, developed the protocol 
(available at NEJM.org) and was responsible for 
the conduct and oversight of the trial, as well as 
the interpretation of the data. Pharmaceutical 
Product Development was responsible for the col-
lection and handling of the data. The protocol 
was approved by the Food and Drug Administra-
tion and a central institutional review board. All 
data analyses were performed by PhaseBio Phar-
maceuticals. The first author wrote the first draft 
of the manuscript, and all the authors participated 
in revisions of subsequent drafts. No one who is 
not an author contributed to writing the manu-
script. The authors vouch for the completeness and 
accuracy of the data and analyses and for the fi-
delity of the trial to the protocol.
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Eligibility
Eligible volunteers were healthy men and women 
18 to 50 years of age, with a weight of 50 to 120 kg 
and a body-mass index (the weight in kilograms 
divided by the square of the height in meters) of 
18 to 35. Volunteers who had any contraindication 
to ticagrelor, a medical history suggestive of an 
increased bleeding risk, or an estimated glomeru-
lar filtration rate of less than 60 ml per minute 
per 1.73 m2 of body-surface area were excluded. 
Written informed consent was obtained from all 
volunteers. No effort was made to balance the 
groups on the basis of age, race or ethnic group, 
or sex.
Outcomes
The primary efficacy outcome was reversal of the 
antiplatelet effects of ticagrelor as assessed by 
analysis of platelet aggregation with the use of 
light transmission aggregometry at multiple time 
points before and after the administration of 
PB2452 or placebo in volunteers who were pre-
treated with ticagrelor. Secondary efficacy out-
comes were ticagrelor reversal as assessed with 
the use of a point-of-care P2Y12 platelet-reactivity 
test known as the VerifyNow P2Y12 assay (Accriva) 
and a vasodilator-stimulated phosphoprotein 
(VASP) phosphorylation immunoassay known as 
the modified CY-QUANT VASP P2Y12 assay (Bio-
Cytex). Details regarding these assays and the in-
terpretation of their results are provided in the 
Methods section of the Supplementary Appendix.
The primary safety outcome was the frequency 
and severity of adverse events that occurred after 
the initiation of PB2452 or placebo. Association 
of adverse events with PB2452, both in volunteers 
who received ticagrelor pretreatment and in those 
who did not, was determined by the investigator. 
Clinical laboratory test results, vital signs, results 
of 12-lead electrocardiography and continuous 
telemetry, and findings on physical examination 
were also obtained at multiple time points from 
screening to the end of the 28-day safety follow-
up period. The immunogenicity of PB2452 was 
assessed before the administration of PB2452, as 
well as 7 days and 28 days afterward. Other sec-
ondary outcomes included the pharmacokinetic 
profiles of PB2452 and ticagrelor.
Statistical Analysis
The sample of 64 volunteers was an ad hoc deci-
sion that was based on the requirement that 4 or 
8 volunteers be randomly assigned, in a 3:1 ra-
tio, to receive either PB2452 or placebo in each 
dose cohort to explore adequately the safety, ef-
ficacy, and pharmacokinetic profiles of PB2452 
in healthy volunteers. Reversal of the antiplatelet 
effects of ticagrelor was evaluated by comparing 
the platelet aggregation after treatment, which 
was expressed as a percentage of the platelet ag-
gregation at baseline, between PB2452 and pla-
cebo with the use of the Wilcoxon rank-sum test. 
For efficacy data, baseline was defined as the 
time point immediately before the administration 
of ticagrelor. The Bonferroni method was used to 
adjust for multiple comparisons. Correlation of 
results between platelet-function tests was evalu-
ated with the use of Pearson’s correlation coeffi-
cient and Spearman’s rank-correlation coefficient.
Mean data from volunteers who received pla-
cebo were pooled across cohorts for all analyses. 
Results for categorical variables are summarized 
with frequencies and percentages, and results for 
continuous variables are presented with the num-
ber of volunteers with nonmissing data, as well as 
means with standard deviations and medians with 
ranges. Descriptive statistics are presented for each 
cohort and for pooled placebo and PB2452 data. 
Platelet aggregation results were compared be-
tween each PB2452 cohort and pooled placebo 
data (with data for cohorts 4, 5, and 6 and data 
for cohorts 7 through 10 pooled separately). All 
analyses were performed with SAS software, ver-
sion 9.4 (SAS Institute). Details regarding all sta-
tistical analyses are provided in the protocol, 
which includes the statistical analysis plan.
R esult s
Trial Population
From April 3, 2018, to August 23, 2018, a total of 
64 volunteers underwent randomization, of whom 
48 were assigned to receive PB2452 and 16 to re-
ceive placebo. Of the 48 volunteers who received 
PB2452, 21 received the highest dose (18 g) and 
39 received ticagrelor pretreatment. Details re-
garding the final trial design and regarding en-
rollment, randomization, and follow-up are shown 
in Table S1 and Figure S1, respectively, in the 
Supplementary Appendix. Characteristics of the 
volunteers at baseline are shown in Table 1.
Safety
A total of 30 adverse events that occurred after 
initiation of PB2452 or placebo were reported by 
19 of the 64 volunteers (30%). Of the 48 volunteers 
The New England Journal of Medicine 
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who received PB2452, 17 (35%) reported 27 adverse 
events; of the 16 volunteers who received placebo, 
2 (12%) reported 3 adverse events (Table 2). There 
were no dose-limiting toxic effects or infusion-
related reactions. There were no deaths or adverse 
events that led to discontinuation of the trial drug 
or hospitalization. One volunteer had 2 serious 
adverse events (alcohol poisoning and acute re-
spiratory failure) 4 days after discharge from the 
clinical site. Except for 2 volunteers, in cohorts 
1 and 3, all volunteers with adverse events had 
received ticagrelor pretreatment. Changes in mean 
clinical laboratory test results, vital signs, and 
electrocardiographic results were similar across 
cohorts among volunteers who received different 
doses or regimens of PB2452 and were similar 
among those who received PB2452 and those who 
received placebo.
Of the 48 volunteers who received PB2452, 21 
(44%) had detectable antidrug antibodies in blood 
obtained 7 days, 28 days, or both after exposure; 
15 (31%) had been positive before they received 
PB2452 and 6 (12%) became positive after they 
received PB2452, albeit with low titers of 40 (in 
5 volunteers) and 160 (in 1 volunteer). Of the 16 
volunteers who received placebo, 3 (19%) were 
positive for antidrug antibodies, with 2 (12%) hav-
ing preexisting antibodies. All antibody titers were 
less than 1280, and the presence of these anti-
bodies had no observed effect on the safety or 
efficacy of PB2452.
Ticagrelor Reversal
Ticagrelor reversal was assessed in cohorts 4 
through 10 by analysis of platelet aggregation. 
Volunteers in these cohorts were pretreated with 
ticagrelor for 48 hours before they received PB2452 
or placebo. Among volunteers who received pla-
cebo, platelet aggregation was suppressed by 80 to 
85% after 48 hours of ticagrelor pretreatment and 
remained suppressed for an additional 24 hours 
after ticagrelor cessation. Platelet aggregation 
gradually returned closer to normal between 24 
and 48 hours after the initiation of placebo (Fig. 1). 
Volunteers in cohorts 5 and 6 who received a 
30-minute infusion of PB2452 at a dose of 3.0 g 
and 9.0 g, respectively, had a significantly greater 
increase in platelet aggregation than those who 
received placebo. Maximal ticagrelor reversal 
occurred at 30 minutes, immediately after com-
pletion of the 30-minute infusion. The duration 
of reversal was dose-dependent and lasted 1 to 
2 hours (Fig. 1A).
To attain more rapid and sustained ticagrelor 
reversal, the total dose of PB2452 was increased to 
18 g in cohorts 7 through 10 to accommodate the 
administration of an initial bolus and longer infu-
sions of 8, 12, and 16 hours. In cohort 7, PB2452 
was administered as a 3.0-g bolus followed by an 
8-hour infusion. Although use of this regimen 
significantly extended the duration of reversal to 
Characteristic
Placebo 
(N = 16)
PB2452 
(N = 48)
Age — yr 34.0±8.3 30.5±8.8
Sex — no. (%)
Male 11 (69) 23 (48)
Female 5 (31) 25 (52)
Weight — kg 86.2±13.5 78.2±14.8
Height — cm 173.3±6.4 167.8±10.2
Body-mass index† 28.6±3.3 27.7±4.1
Race or ethnic group — no. (%)‡
White 7 (44) 27 (56)
Black 8 (50) 18 (38)
Asian 0 1 (2)
American Indian or Alaska Native 1 (6) 0
Native Hawaiian or Pacific Islander 0 1 (2)
Multiple 0 1 (2)
Hispanic ethnic group — no. (%)‡
Hispanic 6 (38) 22 (46)
Not Hispanic 10 (62) 26 (54)
Platelet count per mm3 239,000±52,100 253,000±46,800
Platelet aggregation on light transmis-
sion aggregometry — %§
82.1±7.5 82.9±7.5
Platelet reactivity units on point-of-care 
P2Y12 platelet-reactivity test¶
226.4±39.9 237.7±36.8
Platelet reactivity index on VASP assay‖ 89.8±4.2 90.2±3.6
*  Plus–minus values are means ±SD. In general, the baseline value was defined 
as the last nonmissing measurement obtained before randomization. There 
were no significant differences between the groups with regard to baseline 
characteristics.
†  The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡  Race or ethnic group was reported by the volunteer.
§  On light transmission aggregometry, the normal range for platelet aggrega-
tion is 72 to 94% (CirQuest Labs in-house validation).
¶  On the point-of-care P2Y12 platelet-reactivity test (VerifyNow P2Y12 assay), the 
normal range for platelet reactivity units is 180 to 380 (Accriva package insert).
‖  On the vasodilator-stimulated phosphoprotein (VASP) assay (modified  
CY-QUANT VASP P2Y12), the normal range for the platelet reactivity index  
is 89 to 99% (BioCytex package insert).
Table 1. Characteristics of the Volunteers at Baseline.*
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approximately 12 hours, the onset of reversal was 
delayed by approximately 2 hours (Fig. 1B). In 
cohorts 8, 9, and 10, PB2452 was administered 
as a 6.0-g bolus followed by a 12-hour or 16-hour 
infusion. With the larger bolus, reversal occurred 
within 5 minutes after initiation of the infusion 
and was sustained for 16 to 24 hours (Fig. 1B). 
Overall, in cohorts 7 through 10, in which the 
PB2452 regimen was adjusted to include an initial 
bolus for rapid reversal and a prolonged infusion 
for sustained reversal, volunteers who received 
PB2452 (pooled) had a significantly greater in-
crease in platelet aggregation than those who 
received placebo (pooled) across all time points 
between 5 minutes and 20 hours (P<0.001 after 
Bonferroni adjustment).
The significant immediate and sustained ti-
cagrelor reversal that was detected with light trans-
mission aggregometry in the primary efficacy 
analysis was confirmed with the point-of-care 
P2Y12 platelet-reactivity test and VASP assay (Fig. 
S2A and S2B in the Supplementary Appendix). Cor-
relation analyses of results on the three platelet-
function tests revealed significant correlation for 
all comparisons, with r values of 0.91 or higher and 
0.81 or higher for the Pearson’s and Spearman’s 
analyses, respectively (P<0.001 for all comparisons) 
(Fig. S3 in the Supplementary Appendix).
To assess the extent to which normal platelet 
function was restored, in cohorts 9 and 10 (pooled), 
platelet function after the initiation of PB2452 was 
compared with platelet function at baseline (before 
the administration of ticagrelor) with the use of 
all three assays. On light transmission aggregome-
try, the mean platelet aggregation was restored 
to a normal level (≥80% of the baseline value) at 
all time points up to 20 hours (Fig. 2A). On the 
point-of-care P2Y12 platelet-reactivity test, the mean 
platelet reactivity reflected rapid and sustained 
normalization of platelet function, with a level of 
platelet reactivity units of at least 180, for 24 hours 
(Fig. 2B). On assessment of P2Y12 receptor signal-
ing with the VASP assay, the platelet reactivity in-
dex was restored to nearly 100% of the baseline 
value within 5 minutes and remained at that level 
for 20 to 24 hours (Fig. 2C).
To determine whether acute ticagrelor reversal 
causes a potentially prothrombotic rebound effect 
in platelet reactivity, platelet aggregation was as-
sessed in response to a low concentration of ad-
enosine diphosphate (5 μM, as compared with the 
usual 20 μM). In addition, platelet aggregation was 
assessed in response to other agonists, including 
arachidonic acid and thrombin receptor–activating 
peptide. As expected, the response was lower with 
5 μM of adenosine diphosphate than with 20 μM 
(Fig. S4A and S4B in the Supplementary Appen-
dix), and the responses to arachidonic acid and 
thrombin receptor–activating peptide after reversal 
were similar to the responses at baseline (before 
the administration of ticagrelor) (Fig. S4C and 
S4D in the Supplementary Appendix).
Pharmacokinetics
Pharmacokinetic analysis of PB2452 revealed 
dose-linear increases in mean exposure (maximum 
Variable
Placebo 
(N = 16)
PB2452 
(N = 48)
Any event — no. 3 27
Volunteers with event — no. (%)† 2 (12) 17 (35)
Bruising at infusion site 0 4 (8)
Reaction at medical device site 0 3 (6)
Bruising at vessel puncture site 0 2 (4)
Extravasation at infusion site 0 2 (4)
Abdominal pain 0 1 (2)
Acute respiratory failure 0 1 (2)
Alcohol poisoning 0 1 (2)
Aspiration pneumonia 0 1 (2)
Blood in urine 0 1 (2)
Conjunctivitis 0 1 (2)
Contusion 1 (6) 0
Dizziness 0 1 (2)
Eyelid irritation 1 (6) 0
Gastroenteritis 0 1 (2)
Hematuria 0 1 (2)
Musculoskeletal chest pain 1 (6) 0
Nasopharyngitis 0 1 (2)
Oropharyngeal pain 0 1 (2)
Reaction at infusion site 0 1 (2)
Skin abrasion 0 1 (2)
Streptococcal pharyngitis 0 1 (2)
Upper limb fracture 0 1 (2)
*  Shown are adverse events that occurred after initiation of PB2452 or placebo. 
The terms are based on codes from the Medical Dictionary for Regulatory 
Activities, version 21.0.
†  For each entry, a volunteer is counted once if he or she reported one or more 
events.
Table 2. Adverse Events.*
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concentration and area under the curve from 0 to 
48 hours [AUC0–48 hours]) across the dose range of 
1.0 to 9.0 g. Clearance was approximately 2.5 li-
ters per hour. The elimination half-life and vol-
ume of distribution varied across the dose range. 
Among volunteers who received placebo and ti-
cagrelor pretreatment, the mean AUC0–48 hours for 
ticagrelor ranged from 4730 to 6750 hours times 
nanograms per milliliter. Among volunteers who 
received 30-minute infusions of PB2452 and ti-
cagrelor pretreatment, the mean AUC0–48 hours for 
ticagrelor was increased by a factor of 2.0 to 5.6. 
Figure 1. Onset and Duration of Ticagrelor Reversal.
Ticagrelor reversal is shown as an increase in mean platelet aggregation after ticagrelor pretreatment, as assessed 
with the use of light transmission aggregometry. Shown are the onset and duration of ticagrelor reversal among vol-
unteers in cohorts 4, 5, and 6, who were randomly assigned to receive either a 30-minute infusion of PB2452 at a dose 
of 1 g, 3 g, and 9 g, respectively, or placebo (Panel A), as well as among volunteers in cohorts 7, 8, 9, and 10, who 
were randomly assigned to receive an 18-g fixed dose of PB2452 with an infusion duration of 8 hours, 12 hours, 16 
hours, and 16 hours, respectively, or placebo (Panel B). Mean platelet aggregation at baseline (before the adminis-
tration of ticagrelor) is shown at −48 hours. P values are for the comparison of PB2452 with placebo. Statistical test-
ing was not performed in cohort 9 because only three volunteers in that cohort received PB2452. I bars indicate the 
standard deviation. NA denotes not available.
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Figure 2. Normalization of Platelet Function after Ticagrelor Reversal.
Normalization of platelet function is shown as an increase in platelet function to within the normal range after tica-
grelor pretreatment and subsequent initiation of PB2452. Shown are data from cohorts 9 and 10 (pooled). On light 
transmission aggregometry (Panel A), a normal level of platelet aggregation is at least 80% of the baseline value 
(dashed line). On the point-of-care P2Y12 platelet-reactivity test (Panel B), a normal level of platelet reactivity units 
is at least 180 (dashed line). On assessment of P2Y12 receptor signaling with the vasodilator-stimulated phospho-
protein (VASP) assay (Panel C), a normal platelet reactivity index is at least 80% of the baseline value (dashed line). 
Red diamonds indicate the mean, horizontal lines the median, and I bars the range. The tops and bottoms of the 
boxes indicate the third and first quartiles, respectively.
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Among volunteers who received 18 g of PB2452 
with longer infusions and ticagrelor pretreatment, 
PB2452 exposure was maintained for 12 to 24 
hours, and the mean AUC0–48 hours for ticagrelor 
was increased by a factor of 5.6. The increased 
ticagrelor exposure probably reflected tight bind-
ing between PB2452 and ticagrelor and redistri-
bution of extravascular ticagrelor into the vascular 
compartment. Details regarding the pharmaco-
kinetic profiles of PB2452 and ticagrelor are pro-
vided in Figure S5A through S5D in the Supple-
mentary Appendix.
Discussion
In this trial, intravenous infusion of the mono-
clonal antibody fragment PB2452 significantly 
reversed the antiplatelet effects of ticagrelor, as 
measured by multiple assays of platelet function. 
In the healthy trial population, there were no seri-
ous adverse events or infusion-related reactions 
that were determined to be associated with PB2452. 
It remains unclear whether reversal of the anti-
platelet effects of ticagrelor by PB2452 would lead 
to more rapid hemostasis in patients with bleed-
ing or to prevention of bleeding in patients who 
are undergoing urgent invasive procedures.
The ability to reverse the action of novel oral 
anticoagulants has been a major advance in anti-
thrombotic therapy.30,31 Currently, no effective 
methods for reversal of the antiplatelet effects of 
oral P2Y12 antagonists, such as ticagrelor, are avail-
able other than stopping the drug and waiting 
3 to 5 days for its effects to dissipate, a method 
that is problematic in patients who have life-
threatening bleeding or a high risk of thrombo-
sis. Treatment guidelines and prescription infor-
mation for P2Y12 inhibitors recommend drug 
cessation 3 to 7 days before surgical procedures. 
Waiting this long is impossible in patients who 
are undergoing emergency surgery and may be 
inadvisable for those who are undergoing urgent 
surgery. Platelet transfusion may be considered 
for attempting reversal of aspirin and some P2Y12 
receptor antagonists but is not useful in patients 
who are receiving ticagrelor, because the free drug 
binds to fresh platelets.32,33 Therefore, a ticagrelor 
reversal agent would be useful.
PB2452 is a recombinant human IgG1 mono-
clonal antibody antigen-binding fragment that 
binds with high affinity and specificity to rap-
idly neutralize ticagrelor and its active metabolite 
AR-C124910XX.28 The high affinity and specificity 
of PB2452 enables it to neutralize free ticagrelor 
and prevent binding to the P2Y12 receptor. These 
properties explain the immediate reversal that was 
observed with PB2452, and such reversal is a key 
feature for patients with hemorrhage. The 
mechanism of action is expected to be specific 
to ticagrelor and not work with clopidogrel or 
prasugrel, which are irreversible P2Y12 receptor 
antagonists.
There are some limitations of this trial. The 
trial involved healthy volunteers and not patients 
with atherosclerosis. The sample size was small. 
Because the trial involved healthy volunteers and 
not patients with bleeding who were already taking 
ticagrelor, the results may not be predictive of the 
reversal or safety profile of PB2452 in that patient 
population or the effect of PB2452 on the establish-
ment of hemostasis or the prevention of bleeding.
Several clinical studies that have used the same 
assays have correlated platelet inhibition with 
bleeding risk.34-36 In a literature review and expert 
consensus statement and in a large meta-analysis 
of 17 clinical trials that included more than 20,000 
patients who were undergoing percutaneous cor-
onary intervention and whose platelet function 
was measured with the use of a point-of-care P2Y12 
platelet-reactivity test or a VASP assay, low plate-
let reactivity was independently associated with 
an elevated bleeding risk.37,38 In this trial involving 
volunteers who were pretreated with ticagrelor, 
low platelet reactivity was rapidly reversed by a new 
targeted monoclonal antibody fragment.
In conclusion, we found that the administra-
tion of intravenous PB2452 reversed the antiplate-
let effects of ticagrelor, as measured by multiple 
assays of platelet function, and was associated 
with minimal low-grade toxic effects.
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